Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus (Q35621741)

9 August 2017

1 reference

title

Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus (English)

1 reference

9 August 2017

1 reference

1 reference

1 reference

2

Thierry Poynard

1 reference

9 August 2017

Yves Benhamou

1

1 reference

9 August 2017

publication date

1 January 2003

1 reference

9 August 2017

published in

Journal of Hepatology

1 reference

9 August 2017

volume

39 Suppl 1

1 reference

9 August 2017

page(s)

S194-9

1 reference

Hepatitis B virus infection in the acquired immunodeficiency syndrome

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Interferon alfa treatment of chronic hepatitis B: Randomized trial in a predominantly homosexual male population

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Identification of factors influencing response rate to antiviral therapy of chronic hepatitis B virus infection. A review of the efficacy of adenine arabinoside and lymphoblastoid interferon in the Royal Free Hospital studies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Elevated liver enzymes following initiation of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900321-0

7 January 2021

10.1016/S0168-8278(03)00321-0

Identifiers

DOI

1 reference

9 August 2017

1 reference